Open Access Articles- Top Results for Neratinib


File:Neratinib skeletal.svg
Systematic (IUPAC) name
Clinical data
698387-09-6 7pxN
PubChem CID 9915743
ChemSpider 8091392 7pxY
KEGG D08950 7pxY
ChEMBL CHEMBL180022 7pxY
Chemical data
Formula C30H29ClN6O3
557.04 g/mol
 14pxN (what is this?)  (verify)

Neratinib (HKI-272) is a tyrosine kinase inhibitor[1][2] under investigation for the treatment breast cancer[3] and other solid tumours.

It is in development for the treatment of early- and late-stage HER2-positive breast cancer.[4]

Like lapatinib and afatinib, it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.[5]

Clinical trials

Neratanib is being developed by Puma Biotechnology. It will be included in the forthcoming I-SPY2 breast cancer trial.[6]

Mechanism of action

Neratinib inhibits the epidermal growth factor receptor by covalently binding with a cysteine side chain in that protein.[7]


  1. ^ "Definition of neratinib - National Cancer Institute Drug Dictionary". Retrieved 2008-12-01. 
  2. ^ Rabindran SK, Discafani CM, Rosfjord EC et al. (June 2004). "Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase". Cancer Res. 64 (11): 3958–65. PMID 15173008. doi:10.1158/0008-5472.CAN-03-2868. 
  3. ^ Clinical trial number NCT00398567 for "A Phase 1/2 Study Of HKI-272 In Combination With Herceptin In Subjects With Advanced Breast Cancer" at
  4. ^ "Puma Acquires Global Rights to Pfizer’s Phase III Breast Cancer Drug Neratinib". 
  5. ^ Minami Y, Shimamura T, Shah K et al. (July 2007). "The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272". Oncogene 26 (34): 5023–7. PMID 17311002. doi:10.1038/sj.onc.1210292. 
  6. ^ "Breast cancer study aims to speed drugs, cooperation" March 2010
  7. ^

Lua error in package.lua at line 80: module 'Module:Buffer' not found.